🇺🇸 FDA
Pipeline program

Oral Encochleated Amphotericin B (CAMB)

MB-70008

Phase 2 small_molecule terminated

Quick answer

Oral Encochleated Amphotericin B (CAMB) for Vulvovaginal Candidiases is a Phase 2 program (small_molecule) at Matinas BioPharma Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Matinas BioPharma Holdings
Indication
Vulvovaginal Candidiases
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials